Cetrorelix (3mg)

What is Cetrorelix?

A third-generation GnRH receptor antagonist that immediately blocks LH/FSH release without the initial flare seen with agonists.

Listed vial contents: 3mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Cetrorelix is a synthetic decapeptide GnRH antagonist with multiple non-natural amino-acid substitutions that confer high receptor affinity and protease resistance. Competitive blockade of pituitary GnRH receptors produces immediate suppression of LH and FSH secretion without the flare phase characteristic of GnRH agonists.

What are the research questions?

• Assisted reproduction: FDA-approved as Cetrotide® to prevent premature LH surges in controlled ovarian stimulation.
• Endometriosis and fibroids: Studied for hormone-dependent gynecologic conditions.
• Benign prostatic hyperplasia and prostate cancer: Investigated as an alternative to GnRH agonists where flare avoidance is critical.
• GnRH receptor research: A reference antagonist for pituitary pharmacology.

What does the published work describe?

Olivennes F et al. (Hum Reprod 2000) — comparable IVF outcomes to long agonist protocols with shorter treatment duration. Established efficacy across the ART literature.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Olivennes F et al. Hum Reprod 2000
2. Reissmann T et al. Hum Reprod Update 2000

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.

How is Cetrorelix handled in the lab?

Plan a Cetrorelix stock solution from the sequence, the listed molecular weight (1431.06 g/mol) and, when reported for the same lot, net peptide content. Test-dissolve a small portion first, store the powder sealed, cold and dry, and split solutions into single-use aliquots. These are laboratory handling notes, not administration guidance.

• Peptide solubility: choosing a lab solvent
• Stock solution molarity and concentration math
• Lyophilized storage, aliquoting and freeze-thaw
• Fmoc vs Boc synthesis and the impurities they leave